Consumer views on the use of digital tools for reporting adverse drug reactions: a cross-sectional study

被引：0

作者：

Dedefo, Mohammed Gebre ^{[1
]}

Lim, Renly ^{[1
]}

Kassie, Gizat M. ^{[1
]}

Gebreyohannes, Eyob Alemayehu ^{[1
]}

Salekdeh, Nava Nikpay ^{[2
]}

Roughead, Elizabeth ^{[1
]}

Kalisch Ellett, Lisa ^{[1
]}

机构：

[1] Univ South Australia, Qual Use Med & Pharm Res Ctr, UniSA Clin & Hlth Sci, Adelaide, Australia

[2] Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, Australia

来源：

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2025年 / 47卷 / 02期

关键词：

Adverse drug reaction reporting systems; Consumer behavior; Digital technology; Drug-related side effects and adverse reactions; Mobile applications; Pharmacovigilance; HEALTH-CARE PROFESSIONALS; MOBILE APP; INFORMATION; TECHNOLOGY; ACCEPTANCE; MOTIVES;

D O I：

10.1007/s11096-024-01847-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BackgroundThe application of digital technologies has shown benefits in enhancing pharmacovigilance activities but consumers views on the use of these tools for this purpose are not well described. AimTo explore consumers' views on using digital tools to report adverse drug reactions (ADRs) and identify key features that consumers want in digital tools for ADR reporting. MethodAn online survey was conducted among adults who had taken medicine in the previous six-months in Australia. The development of questions was guided by the Combined Technology Acceptance Model and Theory of Planned Behaviour (C-TAM-TPB) framework. Responses to closed-ended questions were analysed using descriptive statistics and chi-square/Fisher's exact test, while free-text responses were analysed using qualitative content analysis. ResultsA total of 494 responses were included in the analysis. Eighty-seven percent of respondents preferred using digital tools for reporting ADRs. Consumers indicated a free-text space for describing ADRs (90%) as important or very important features of digital tools for ADR reporting, followed by acknowledgement of their report submission (87%) and receiving summary of previously reported ADRs (87%). Women (p < 0.001), advanced smartphone users (p < 0.001), and previous digital healthcare tool users (p = 0.017) showed higher intention to use digital tools. Consumers emphasized the importance of ease-of-use, accessibility, receiving medicine safety information, feedback, and advice for reporting ADRs via digital tools. ConclusionConsumers prefer using digital tools for reporting ADRs and place high value on features such as a free-text space for describing ADRs, acknowledgement of report submissions, and access to summaries of previously submitted reports.

引用

页码：423 / 434

页数：12

共 47 条

[11]

Costa C., Abeijon P., Rodrigues D.A., Et al., Factors associated with underreporting of adverse drug reactions by patients: a systematic review, Int J Clin Pharm, 45, pp. 1349-1358, (2023)

[12]

Shafei L., Mekki L., Maklad E., Et al., Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework, Int J Clin Pharm, 45, pp. 801-813, (2023)

[13]

Inacio P., Cavaco A., Airaksinen M., Current trends in pharmacovigilance: value and gaps of patient reporting, Int J Clin Pharm, 40, pp. 754-757, (2018)

[14]

Madhushika M.T., Weerarathna T.P., Liyanage P., Et al., Evolution of adverse drug reactions reporting systems: paper based to software based, Eur J Clin Pharmacol, 78, 9, pp. 1385-1390, (2022)

[15]

Fukushima A., Iessa N., Balakrishnan M.R., Et al., Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience, BMC Med Inform Decis Mak, 22, 1, (2022)

[16]

Xia X., Yang X., Du J., Et al., Exploring willingness to use adverse drug reaction reporting systems: a multicentre qualitative study in China based on the technology acceptance model and task-technology fit integration approach, BMJ Open, (2024)

[17]

Adedeji-Adenola H., Nlooto M., Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review, Int J Clin Pharm, 43, pp. 11-24, (2021)

[18]

Ribeiro-Vaz I., Silva A.M., Costa Santos C., Et al., How to promote adverse drug reaction reports using information systems—a systematic review and meta-analysis, BMC Med Inform Decis Mak, 16, (2016)

[19]

Hasford J., Bruchmann F., Lutz M., Et al., A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues, Eur J Clin Pharmacol, 77, 11, pp. 1697-1704, (2021)

[20]

Hunsel F.V., Harmark L., Pal S., Et al., Experiences with adverse drug reaction reporting by patients: an 11-country survey, Drug Saf, 35, 1, pp. 45-60, (2012)

← 1 2 3 4 5 →